Lucentis (Ranibizumab injection)


Lucentis® (ranibizumab injection) is a prescription medicine for the treatment of people with wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).

Lucentis was developed by Genentech, a member of the Roche Group. Genentech retains commercial rights in the US and Novartis has exclusive commercial rights for the rest of the world.